研究单位：[1]Pfizer[2]University of Alabama at Birmingham[3]Rheumatology Associates of North Alabama, PC[4]Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550
A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550
